Once-daily topical treatment of target cutaneous neurofibromas (cNFs) with NFX‑179 Gel 1.5% achieved statistically significant reduction in size First randomized, double-blind, vehicle-controlled Phase 2b clinical trial to report positive results in the treatment of cutaneous…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.